{"id":"W3168005110","doi":"10.1055/s-0041-1730167","title":"IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)","year":2021,"lang":"en","type":"article","venue":"Senologie - Zeitschrift für Mammadiagnostik und -therapie","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Atezolizumab; Placebo; Oncology; Medicine; Paclitaxel; Breast cancer; Internal medicine; Doxorubicin; Cyclophosphamide; Quality of life (healthcare); Stage (stratigraphy); Triple-negative breast cancer; Chemotherapy; Cancer; Pembrolizumab; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001254835,0.0008044639,0.002658285,0.0005148228,0.0001665208,0.00006054548,0.0004874449,0.0005951482,0.0006914031],"category_scores_gemma":[0.00859968,0.0006646875,0.0003202092,0.001490871,0.0006289351,0.0002189139,0.0005885481,0.001413502,0.00001737554],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003004247,"about_ca_system_score_gemma":0.002556742,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0876544,"about_ca_topic_score_gemma":0.009958864,"domain_scores_codex":[0.9908871,0.001236616,0.003307988,0.00170449,0.001700621,0.00116315],"domain_scores_gemma":[0.990319,0.004578864,0.001409726,0.001911518,0.001095297,0.0006856514],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02611805,0.008422855,0.8179635,0.0003309853,0.004376023,0.002206525,0.01655502,0.0003410517,0.005117412,0.0001126212,0.0007121978,0.1177438],"study_design_scores_gemma":[0.04078511,0.002483462,0.9402105,0.0007587646,0.0003024804,0.00002184411,0.005456445,0.00009785962,0.006746248,0.00003950673,0.002486551,0.0006112531],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980471,0.006150181,0.00001091732,0.004772826,0.0004598829,0.003343106,0.003899679,0.0001265106,0.0007659417],"genre_scores_gemma":[0.9949417,0.003358845,0.0003363699,0.0003898951,0.000119861,0.0002003133,0.0002013382,0.0001173585,0.0003343282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.122247,"threshold_uncertainty_score":0.9997513,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0626525346854209,"score_gpt":0.3918539450723508,"score_spread":0.32920141038693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}